| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
2 companies
Emily Luisa Hill is Chief Financial Officer at REPL, with reported holdings spanning 2 companies. Emily Luisa Hill's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $7.1M at current prices.
Our model assigns Emily Luisa Hill a middling insider score of 59/100, based on 15 past trades. Over a 12-month horizon, 64.3% of those trades were profitable, with an average 12-month return of +10.8%.
Emily Luisa Hill's largest disclosed position is in REPL as Chief Financial Officer, worth about $4.5M. The REPL filings lean toward selling, a net 49,143 shares.
Emily Luisa Hill has 32 Form 4 filings on record from May 2019 to August 2026, across 2 companies: Chief Financial Officer at Replimune Group (REPL), 2023–2026; Chief Financial Officer at Ptc Therapeutics (PTCT), 2019–2023.
The 52 reported transactions were 30 open-market sales, 9 stock awards, 9 option or other derivative awards and 4 option exercises.
Counted by filing, the open-market trades come to no purchases and 23 sales worth about $3.3M.
The largest open-market sale was 26,033 shares of PTCT at an average $69.75 on January 8, 2021, about $1.8M.
None of the 6 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 9,256 | $14.28 | $132,175.68 | -4.1% | - | - | |
| Aug 10, 2026 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 11,448 | $12.97 | $148,480.56 | -4.8% | - | - | |
| May 18, 2026 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 7,812 | $5.08 | $39,684.96 | -3.2% | +192.0% | - | |
| Aug 15, 2025 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 9,154 | $5.37 | $49,156.98 | -6.4% | +61.5% | +169.2% | |
| May 20, 2025 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 2,535 | $8.05 | $20,406.75 | -1.7% | -42.0% | -43.9% | |
| Aug 16, 2024 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 8,938 | $10.18 | $90,988.84 | -8.1% | +12.8% | -45.0% | |
| Mar 27, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Financial Officer | Sell | 7,363 | $45.00 | $331,335.00 | -15.9% | -11.7% | -38.9% | |
| Jan 31, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Financial Officer | Sell | 575 | $45.63 | $26,236.10 | -1.2% | +20.2% | -43.1% | |
| Jan 24, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Financial Officer | Sell | 223 | $47.45 | $10,581.64 | -0.5% | +11.8% | -42.4% | |
| Jan 11, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Financial Officer | Sell | 915 | $43.58 | $39,879.96 | -1.9% | +6.1% | -37.1% |